#USA #New Haven #Clinical Trials #Prism #Jumo Health

Jumo Health's PRISM™: A New Era in Clinical Trials

Jumo Health, a leading Patient Experience Organization (PXO), has unveiled its latest innovation, PRISM™, a groundbreaking system designed to rethink clinical trial participation. The key insight driving PRISM™ is the recognition that many clinical trial failures stem not from issues related to patient recruitment, but from a lack of patient readiness post-enrollment. By prioritizing the emotional, cognitive, and practical preparations necessary for sustained involvement, PRISM™ aims to enhance the overall effectiveness and predictability of clinical trials.

The Problem with Current Clinical Trials

Despite advances in technology, including AI-driven tools for patient matching and recruitment, many clinical trials struggle with what is referred to as "screen failure" and early dropout rates. Many patients may be deemed medically eligible but are not fully prepared to participate. The assumption that eligibility equates to readiness leads to significant challenges in trial execution, where patients disengage as the trial progresses. According to Brittany Erana, CEO of Jumo Health, this approach is outdated: “Clinical trials have spent decades optimizing how patients are recruited, but little time questioning whether those patients are truly prepared to participate.”

What PRISM™ Offers

PRISM™ proposes a new model that does not just focus on getting patients into trials, but on ensuring they are equipped to complete them successfully. This innovative approach encompasses several key components:
1. Readiness Assessment: PRISM™ examines a patient’s emotional and cognitive readiness alongside their eligibility, ensuring that potential participants are prepared for the challenges of clinical involvement.
2. Dynamic Monitoring: Readiness is treated as a fluid state that is continuously monitored throughout the trial lifecycle, allowing for timely interventions when readiness wanes.
3. Intelligent Pre-Screening: The system leverages behavioral science to identify potential participants who are likely to engage and succeed in a trial setting, thereby protecting retention and completion rates.

This marks a pivotal shift from traditional eligibility-first models toward a comprehensive readiness-based execution framework, ensuring that patient engagement is maintained throughout the trial’s duration.

Why Readiness Matters

The operational insights provided by PRISM™ address the critical question: Is participation likely to hold once the trial becomes real? By refocusing on readiness as a primary execution variable, Jumo Health can identify and act on issues before they lead to costly dropout or protocol deviations. With this system, clinical trials can expect to be more inclusive and complete, thereby increasing the likelihood that trials finish as planned.

The Future of Clinical Trials

As Jumo Health integrates artificial intelligence, real-world data, and human-centered design with patient education and health literacy, the goal remains clear: to reduce friction in clinical trials, alleviate patient fears, and foster trust. PRISM™ provides an operational backbone, enabling biopharmaceutical sponsors and research partners to govern participation more effectively.

With wide-ranging applicability across various therapeutic areas and languages, Jumo Health continues its mission towards transforming clinical trial experiences for patients and caregivers alike. This innovation not only enhances the patient experience but is set to redefine trial execution in the clinical research landscape.

Conclusion

By instilling a culture of preparedness, Jumo Health's PRISM™ systematically enhances patient engagement and retention, paving the way for a more resilient clinical research environment. Ultimately, PRISM™ is about empowering patients with the knowledge and confidence they need to participate fully in trials, ensuring they not only enroll but succeed in completing their commitments.

This advancement in clinical trial methodology stands to benefit patients, researchers, and pharmaceutical companies alike, marking a significant leap forward in the domain of clinical research.